ReviewFrontiers in oncology2020
Traditional Classification and Novel Subtyping Systems for Bladder Cancer.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.Frontiers in oncology · 2024Pooled it
- A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- The staging of re-TURB is crucial in predicting the response to BCG therapy in patients with T1 high-grade bladder cancer.Investigative and clinical urology · 2025Article
- Spectral CT for non-invasive evaluation of bladder cancer grade.Abdominal radiology (New York) · 2025Article
- Diagnostic and Prognostic Potential ofInternational journal of molecular sciences · 2025Article
- Clinicopathological study and molecular subtyping of muscle-invasive bladder cancer (MIBC) using dual immunohistochemical (IHC) markers.Diagnostic pathology · 2025Article
- Progressively exploring and assessing the prognosis of bladder urothelial cancer based on the microenvironment through the integration of multiple databases.Frontiers in molecular biosciences · 2025Article
- Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis:Current medicinal chemistry · 2025Article
- Exploring the role of YES1 kinase in regulating cisplatin resistance through iTRAQ-based quantitative proteomic analysis in urothelial carcinoma.American journal of cancer research · 2025Article
- A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy.Advances in radiation oncology · 2025Article
- Loss of Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Tumor Microenvironment and Response to BCG Immunotherapy in a Murine Orthotopic Model of Bladder Cancer.International journal of molecular sciences · 2024Article
- Prognostic Value of TGF-β Expression in Bladder Cancer: A Systematic Review and Meta-analysis.Urology research & practice · 2024Review
- SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.Cell death & disease · 2024Article
- TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells.World journal of clinical oncology · 2024Article
- TM9SF1 promotes bladder cancer cell growth and infiltration.World journal of clinical oncology · 2024Article
- How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?Molecular diagnosis & therapy · 2024Review
- Advances in sarcopenia and urologic disorders.Frontiers in nutrition · 2024Review
- Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layeredFrontiers in oncology · 2024Article
- The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is the most common tumor in the urinary system, with approximately 420,000 new cases and 160,000 deaths per year. The European Organization for Research and Treatment of Cancer (EOTRC) classifies non-muscular invasive bladder cancer (NMIBC) into low-risk, medium-risk and high-risk groups based on a comprehensive analysis of NMIBC pathological parameters and the risk of recurrence and progression to muscular invasive bladder cancer (MIBC). Traditional classification systems are based on pathologic grading, staging systems, and clinical prognosis. However, the pathological parameters of the tumor cannot fully reflect the "intrinsic characteristics" of bladder cancer, and tumors with a similar pathology exhibit different biological behaviors. Furthermore, although the traditional classification system cannot accurately predict the risk of recurrence or the progression of bladder cancer patients (BCs) individually, this method is widely used in clinical practice because of its convenient operation. With the development of sequencing and other technologies, the genetics-based molecular subtyping of bladder cancer has become increasingly studied. Compared with the traditional classification system, it provides more abundant tumor biological information and is expected to assist or even replace the traditional typing system in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.